EMA Says Trulicity Shortage Is Not Related To A Quality Defect Of The Product Or A Safety Issue; Member States Of Austria, Finland, Greece, Poland And Sweden Are Currently Affected By Shortage Of Trulicity
Portfolio Pulse from Happy Mohamed
The European Medicines Agency (EMA) has clarified that the shortage of Trulicity, a diabetes drug, in Austria, Finland, Greece, Poland, and Sweden is not due to a quality defect or safety issue. The manufacturer of Trulicity is Eli Lilly and Company (LLY).
August 28, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eli Lilly and Company's diabetes drug Trulicity is facing shortages in several European countries. However, the EMA has confirmed that this is not due to any quality or safety issues.
The news directly mentions Eli Lilly and Company (LLY), the manufacturer of Trulicity. The EMA's confirmation that the shortage is not due to quality or safety issues may alleviate potential concerns among investors and customers. However, the shortage itself could impact sales and revenues in the short term, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100